glp-1 shortage guidance MCT2D GLP1-RA and SGLT2-i: Implementation and

However, clinical interest exists regarding tirzepatide's potential role in managing metabolic complications that frequently accompany Hashimoto's disease

Guidelines and Recommendations Regulatory status: Not licensed for use in pregnancy (FDA, EMA)

Taken together, this evidence suggests that the heterogeneity of studies models and the interaction of many adaptive mechanisms might explain the variable results in the recent studies concerning the influence of SGLT2-i treatment on the RAAS, although an activation of intrarenal RAS in chronic treated patients has been excluded (42)

This messaging can make it seem like youre getting the same benefits as FDA-approved GLP-1s like Wegovy (semaglutide) or Zepbound (tirzepatide), but the marketing is extremely misleading